Last reviewed · How we verify
NCT05930444
Multimodal Machine Learning for Auxiliary Diagnosis of Eye Diseases
trial testing Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases in Eye Diseases in 9,825 participants. Completed in 31 March 2024.
10 March 2024
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9,825 |
| Start date | 21 July 2023 |
| Primary completion | 10 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases
Conditions studied
- Eye Diseases — all drugs for Eye Diseases →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
2 Months and older, any sex, with Eye Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With rapid advancements in natural language processing and image processing, there is a growing potential for intelligent diagnosis utilizing chatGPT trained through high-quality ophthalmic consultation. Furthermore, by incorporating patient selfies, eye examination photos, and other image analysis techniques, the diagnostic capabilities can be further enhanced. The multi-center study aims to develop an auxiliary diagnostic program for eye diseases using multimodal machine learning techniques and evaluate its diagnostic efficacy in real-world outpatient clinics.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multimodal machine learning enables AI chatbot to diagnose ophthalmic diseases and provide high-quality medical responses.
Ma R, Cheng Q, Yao J, Peng Z, et al · · 2025 · cited 18× · PMID 39870855 · DOI 10.1038/s41746-025-01461-0 -
Development and evaluation of multimodal AI for diagnosis and triage of ophthalmic diseases using ChatGPT and anterior segment images: protocol for a two-stage cross-sectional study.
Peng Z, Ma R, Zhang Y, Yan M, et al · · 2023 · cited 12× · PMID 38145231 · DOI 10.3389/frai.2023.1323924
Verify or expand the search:
- PubMed search for NCT05930444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Eye Diseases
Currently open trials in the same condition.
- NCT07322302 — RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs) · NA · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT06812845 — Patterns of Eye Diseases Among Patients Attending The Eye Investigation Unit of Sohag University Hospital · recruiting
- NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05930444 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: 15 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing